Abstract: Human scFvs are disclosed which interact with a conformational epitope along the pre-hairpin, N-helix coiled coil structure within the heptad repeat 1 (HR1) region of gp41 of HIV. These antibodies, as well as IgG conversions, are shown to neutralize diverse HIV isolates. Isolated nucleic acid molecules are also disclosed which encode relevant portions of these antibodies, as well as the purified forms of the expressed antibodies or relevant antibody fragments, such as VH and VL chains. The antibody compositions disclosed within this specification may provide for a therapeutic treatment against HIV infection by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV infection. These antibodies will also be useful in assays to identify HIV antiviral compounds as well as allowing for the identification of candidate HIV vaccines, such as HIV peptide vaccines.

Abstract: Embodiments of the invention are related to biosorbable batteries, amongst other things. In an embodiment, the invention includes a biosorbable battery assembly including an anode, a cathode, and a biosorbable separation element. The anode can include an anode material, wherein electrochemical oxidation of the anode material results in the formation of reaction products that are substantially non-toxic. The cathode can include a cathode material, wherein electrochemical reduction of the cathode material results in the formation of reaction products that are substantially non-toxic, the cathode material having a larger standard reduction potential than the material of the anode. The biosorbable separation element can be disposed between the anode and the cathode and can be configured to provide electrical insulation between the anode and the cathode.

Abstract: The invention provides compositions and methods for the treatment of HIV infection, inhibition against drug-resistant strains of HIV-1 and methods of enhancing the anti-HIV potency of peptide inhibitors against drug-resistant strains of HIV-1. In particular, oligomeric C-peptide inhibitors for inhibiting HIV entry into host cells are disclosed.

Abstract: Systems and methods for determining depth of discharge for implantable device batteries are provided. One aspect of this disclosure relates to a method for determining depth of discharge for a battery in an implantable medical device. Voltage recovery of the battery is measured subsequent to a predetermined event. Measured voltage recovery data is stored in a database adapted to store data for one or more devices. Measured voltage recovery data is compared with stored voltage recovery data to determine battery depth of discharge. According to various embodiments, battery capacity consumed is measured using a coulometer and using a capacity-by-voltage device. Measured battery capacity consumed is combined with measured voltage recovery data using a predetermined weighted average, and the combined data is stored in the database. The stored data is used to determine battery depth of discharge, according to an embodiment.

Abstract: Five-Helix protein, which comprises the three N-helices and at least two, but not three, of the three C-helices of the trimer-of-hairpin structure of HIV gp41, separated by linkers, such as amino acid residue linkers, is disclosed. Six-Helix protein, which includes the three N-helices and the three C-helices of the trimer-of-hairpin structure of HIV gp41, separated by linkers, is also disclosed.

Abstract: Five-Helix protein, which comprises the three N-helices and at least two, but not three, of the three C-helices of the trimer-of-hairpin structure of HIV gp41, separated by linkers, such as amino acid residue linkers, is disclosed. Six-Helix protein, which includes the three N-helices and the three C-helices of the trimer-of-hairpin structure of HIV gp41, separated by linkers, is also disclosed.

Abstract: Five-Helix protein, which comprises the three N-helices and at least two, but not three, of the three C-helices of the trimer-of-hairpin structure of HIV gp41, separated by linkers, such as amino acid residue linkers, is disclosed. Six-Helix protein, which includes the three N-helices and the three C-helices of the trimer-of-hairpin structure of HIV gp41, separated by linkers, is also disclosed.

Abstract: An electrochemical cell is presented having an improved separator disposed at the interface of the anode and cathode. In particular, the separator conforms to the contour of the electrode and is thinner than conventional separators made of non-woven fabric. The conformal separator may be formed from combinations of certain polymers and inorganic crosslinking agents.

Abstract: Five-Helix protein, which comprises the three N-helices and at least two, but not three, of the three C-helices of the trimer-of-hairpin structure of HIV gp41, separated by linkers, such as amino acid residue linkers, is disclosed. Six-Helix protein, which includes the three N-helices and the three C-helices of the trimer-of-hairpin structure of HIV gp41, separated by linkers, is also disclosed.

Abstract: This invention pertains to novel electrochemical metal air cells having improved closed circuit voltage characteristics. The improved voltage characteristics are illustrated at a constant load of 51 ohms. The closed circuit voltage during an initial placement into use of the cell of the invention has a decreased voltage drop relative to prior art cells, and recovers to a higher voltage. For example, the closed circuit voltage of the metal air cell drops to a minimum voltage during the first 20 seconds of initial placement into use. The minimum voltage is no more than 22% less than the initial open circuit voltage. This voltage drop is less than the voltage drop of other known metal air cells at 51 ohms. Metal air cells of the invention recover, during the first minute of use, to a closed circuit voltage of at least 79% of the initial open circuit voltage. The value of the open circuit voltage of the metal air cell of the invention is preferably about 1.43 volt.